INTRODUCTION
Intrahepatic congenital portosystemic shunts (CPSS) are less common in dogs than their extrahepatic counterparts, making up approximately 25% to 33% of the total (Berent & Tobias 2009 , Berent & Tobias 2012 . For both types of CPSS, surgical attenuation is recommended to restore normal portal blood flow and resolve clinical signs (Berent & Tobias 2009 , Tivers et al . 2012 , Greenhalgh et al . 2014 , Tivers et al . 2017 ). However, intrahepatic CPSS (IHCPSS) can be challenging to manage surgically due to the location of the vessel within the liver parenchyma (Hunt et al . 1996 , White et al . 1998 , Berent & Tobias 2009 ). Surgical techniques for IHCPSS include suture ligation, ameroid constrictors, cellophane banding and hydraulic occluders (White et al . 1998 , Hunt et al . 2004 , Adin et al . 2006 , Bright et al . 2006 , Mehl et al . 2007 ). Intravascular techniques with hepatic inflow occlusion have been used to allow attenuation of some IHCPSS, which is technically demanding (Breznock et al . 1983 , Hunt et al . 1996 , White et al . 1998 . Some studies have reported a high rate of complications (47% to 77%) and mortality (12·5% to 27·3%) with surgical attenuation of IHCPSS (Komtebedde et al . 1991 , White et al . 1998 , Papazoglou et al . 2002 , Hunt et al . 2004 . Hence, intravascular occlusion with interventional radiology has been recommended to reduce complications and mortality associated with traditional surgical techniques (Weisse et al . 2014 ) . However, there is limited long-term follow-up information on dogs with IHCPSS and only one comparative study, making the evidence base for choosing one technique over another even more challenging (Mehl et al . 2007 , Tivers et al . 2017 .
Only a minority of dogs (approximately 0% to 15·4%) can tolerate complete acute attenuation of their IHCPSS (Hottinger et al . 1995 , White et al . 1998 , Papazoglou et al . 2002 . Dogs can be treated with partial attenuation, but with this technique, there remains a concern over residual shunting and the persistence or recurrence of clinical signs, which has been reported to be as high as 24·3% to 50% (Smith et al . 1995 , White et al . 1998 . Gradual attenuation devices, such as ameroid constrictors and cellophane bands, aim to achieve complete attenuation over a period of weeks (Hunt et al . 2004 , Sereda & Adin 2005 , Mehl et al . 2007 ). However, it is unclear how many dogs achieve complete attenuation, and shunting may persist in a significant proportion (Mehl et al . 2007 ). Additionally, the technical challenge of placing a gradual attenuation device or material around an IHCPSS where the space around the shunt may be restricted can make placement impossible in some dogs. In dogs with IHCPSS or extrahepatic CPSS (EHCPSS) treated with partial suture ligation, a second surgery has been described to attempt complete attenuation in a staged manner (Hottinger et al . 1995 , White et al . 1998 , Burton & White 2001 , Lee et al . 2006 . In three of these studies, a proportion of dogs treated with partial attenuation had repeat surgery to attempt full ligation due to recurrence of clinical signs or persistently increased serum bile acids (Hottinger et al . 1995 , White et al . 1998 , Burton & White 2001 . All 28 of the dogs treated with partial attenuation in one study (Lee et al . 2006 ) and nine of 27 dogs treated with partial ligation in another study (Hottinger et al . 1995 ) had a scheduled repeat surgery, without recurrence of clinical signs. The potential advantage of this technique is that it will ensure complete attenuation of the shunt and therefore reduce the chances of persistent or recurrent clinical signs associated with ongoing shunting. However, this technique has not been reported in detail, particularly the complications and outcomes after the second surgery.
Staged suture ligation has been the routine treatment of IHCPSS in dogs at our institution over the last 15 years. Subjectively, this approach has been associated with good short-and long-term outcomes. It was also our impression that the mortality rate had decreased with time, possibly associated with increased experience with surgical and anaesthetic management and the postoperative care. Historically, dogs were treated with non-steroidal anti-inflammatory drugs (NSAIDs) perioperatively to provide multi-modal analgesia. It was suspected that NSAIDs were associated with mortality, and so, their use was discontinued.
The aim of the current study was to report the short-and long-term outcomes of one-or two-staged suture attenuation to achieve complete closure of IHCPSS in a large cohort of dogs. An additional aim was to report any changes in mortality associated with age at surgery, time period of the study and the use of NSAIDs.
MATERIALS AND METHODS
The medical records of dogs with IHCPSS treated surgically between February 2000 and March 2015 were reviewed. Dogs were included in the study if they had been treated with a complete or partial suture ligation of their IHCPSS. Dogs treated with other surgical methods were excluded. During the study period, a standard surgical protocol was routinely followed in all dogs treated with suture ligation, although anaesthetic and postoperative management was at the discretion of the individuals involved.
Dogs underwent laparotomy and intraoperative mesenteric portovenography as previously described (Lee et al . 2006 ) . The shunt was identified, and the location that would provide the easiest access for ligation was determined, typically the shunt itself, the draining hepatic vein or the supplying portal vein branch. The vessel was dissected to allow two strands of 2 M or 3 M polypropylene (Prolene; Ethicon) or silk (Mersilk; Ethicon) suture material to be passed around it. A mesenteric vein was catheterised with a 20 to 24 g over-the-needle catheter, which was used for portovenography and to measure portal venous pressure. Portovenography was performed using a mobile c-arm unit (Siremobil; Siemens) with a sterile cover. A bolus of 1 mL/kg of iohexol contrast agent (Omnipaque 300; GE Healthcare Limited) was injected under fluoroscopic guidance, creating a series of portovenogram images. This allowed confirmation of portosystemic shunting and provided information on the morphology of the shunt and the intrahepatic portal vasculature. The vessel was temporarily completely attenuated using a Rummel tourniquet, and the portovenogram was repeated, allowing confirmation of the correct location of attenuation and reassessment of the intrahepatic portal vasculature. Dogs were treated with complete or partial suture attenuation with polypropylene or silk (Lee et al . 2006 , Cariou et al . 2009a ). The degree of attenuation was based on subjective and objective assessments of intraoperative portal hypertension during temporary complete attenuation. Subjective assessment included visual inspection of the intestines and pancreas during temporary complete attenuation for signs of portal hypertension, including bowel hypermotility, increased mesenteric arterial pulsations, pancreatic oedema and intestinal and pancreatic cyanosis (Mathews and Gofton 1988) . If these signs were observed, then it was considered that the dog would not tolerate complete attenuation. Portal blood pressure was measured before and during temporary complete attenuation of the vessel using a pressure transducer (Becton Dickinson UK Limited) and a multi-parameter monitor (S/5 Compact Monitor; GE Healthcare Limited) connected to the catheter in the mesenteric vein. The increase in portal pressure before and during temporary complete attenuation and the absolute portal pressure were used to determine whether complete attenuation could be performed (Breznock et al . 1983 , Swalec and Smeak 1990 , Bostwick and Twedt 1995 . Contraindications for complete attenuation were a postattenuation portal pressure of greater than 18 mmHg (20 cm H 2 O), an increase of greater than 8 mmHg (10 cm H 2 O) or a doubling of preattenuation portal pressure value. Additionally, a change in central venous pressure of greater than 1 mmHg or a change in arterial pressure of greater than 5 mmHg were considered contraindications to complete attenuation.
Dogs treated with partial attenuation had a length of polypropylene suture left around the vessel to facilitate subsequent attenuation. A second surgery to attempt complete attenuation was recommended for all dogs that had partial attenuation, regardless of clinical response.
Descriptive data were recorded from the medical record as presented in the results. The cohort was separated into two groups, with the first group being the initial 50% of the dogs that had surgery and the second group being the subsequent 50%. The subjective response to medical management presurgery and the subjective short-term response to surgery, as described in the medical record, was graded by the primary author as follows: good=resolution of clinical signs, moderate=improvement in clinical signs and poor=no improvement in clinical signs or relapse. Intraoperative complications were defined as an adverse surgical event that required intervention to correct. Postoperative complications were defined as an adverse event occurring before hospital discharge. Complications were categorised into neurological, portal hypertension, gastrointestinal and miscellaneous. Postoperative mortality was defined as those dogs that died or were euthanased within 30 days of the surgery. This was further divided into those that died before or after hospital discharge.
Detailed follow-up was available for a proportion of the dogs as part of another study using a Health-Related Quality of Life (HRQOL) questionnaire (currently unpublished data). Followup was conducted for the remaining dogs by telephone calls to the referring veterinary surgeon, owner or both. For dogs that were alive at the time of follow-up, outcome was graded by the primary author based on the information obtained from the owner via the HRQOL questionnaire and telephone calls. The grading was based on a previous study (Mehl et al . 2007 ): excellent=resolution of clinical signs and no medical management/diet; fair=resolution of clinical signs with continued medical management/diet; and poor=recurrent or persistent clinical signs, no response to surgery. Owners were also asked to subjectively rate their dog's quality of life.
Statistical analysis was performed using a statistical software package (PASW Statistics 21·0·0; Education SPSS (UK) Limited IBM). Data were assessed graphically for normality. Median and range were reported for skewed data. Categorical data were reported as percentages.
RESULTS

First surgery
Fifty-five dogs met the inclusion criteria. The first 28 dogs were identified in the first half of the study period (February 2001 to November 2006 , and the subsequent 27 dogs were identified in the second half of the study period (December 2006 to March 2015 . Three dogs were excluded because they were treated with the placement of a cellophane band around their CPSS. No dogs were treated with an ameroid constrictor, hydraulic occluder or endovascular coil embolisation. Signalment data and presurgical information are presented in Table 1 .
Details of surgical variables are presented in Table 2 . Fifty-four dogs were treated using an extravascular approach. The majority, including all left-sided shunts, were ligated directly at their entry to the vena cava or ligation of the draining hepatic vein. The remainder were treated by direct ligation of the shunt via dissection of the liver or by ligation of the portal vein branch supplying the shunt. One dog (central divisional CPSS) required an intravascular approach to shunt attenuation. In total, 10 dogs (18·2%) tolerated a complete ligation, and the remaining 45 dogs (81·8%) tolerated a partial ligation of their CPSS. Two dogs (3·6%) had an additional surgical procedure: one cystotomy and one gastric ulcer biopsy. Eight dogs (14·5%) suffered an intraoperative complication, all of which could tolerate partial attenuation only. Two dogs developed iatrogenic pneumothorax due to dissection of the shunt at the diaphragm. This was identified and treated during surgery. Two dogs had apparent mild hypersensitivity reaction to pethidine, which was treated with a single intravenous dose of chlorpheniramine. Four dogs (7·3%) experienced intraoperative haemorrhage. Three of these dogs (two left and one right divisional) experienced haemorrhage during dissection of the shunt. These dogs all required a blood transfusion, but this did not prevent attenuation. The fourth dog (central divisional) experienced haemorrhage secondary to shunt dissection, and the procedure was aborted without attenuation. This dog also required a blood transfusion. Partial attenuation was achieved at repeat surgery 8 days later.
Twenty-four dogs (43·6%) had a postoperative complication, with four of these dogs suffering two complications each (Table 3 ) . Six out of 10 dogs (60%) that could tolerate a complete ligation and 18 of 45 dogs (40%) that were treated by partial ligation experienced a postoperative complication. Postoperative complications affected 11 of 26 (42·3%) dogs with a left divisional shunt, four of 15 (26·7%) dogs with a right divisional shunt and nine of 14 (64·3%) dogs with a central divisional shunt.
Four dogs (7·3%) died in the immediate postoperative period (see Table 3 for details). Fifty-one dogs (92·7%) were discharged from the hospital. The median duration of hospitalisation was 4 days (range 2 to 13). Two dogs (3·6%) died in the immediate period following discharge from the hospital (see Table 3 for details). Overall, six dogs (10·9%) died within 30 days of surgery, all of which had tolerated partial attenuation only. Six out of 45 dogs (13·3%) treated with partial attenuation died postoperatively compared with none of 10 dogs (0%) that had complete attenuation. The median age of dogs that died during the postoperative period was 6·2 months (range 2·4 to 29·1 months) compared with a median of 18·7 months (range 4·3 to 38·2) for dogs that survived. Five out of 28 dogs (17·9%) that had their surgery in the first part of the study period died during the postoperative period compared with one of 27 dogs (3·7%) that had their surgery in the second part of the study period. Five out of 13 dogs (38·5%) that received NSAIDs died during the postoperative period (up to 30 days) compared with one of 42 dogs (2·4%) that did not receive NSAIDs. All four dogs that died because of confirmed or suspected gastroduodenal haemorrhage received NSAIDs.
Second surgery
Overall, 39 of 45 dogs that were treated with partial attenuation survived the postoperative period. Of the surviving 39 dogs, 36 (92·3%) were re-examined (see Table 4 for details). The other three dogs did not return for postoperative re-examination.
Of 39 dogs, 33 (84·6%) had a second surgery (see Table 5 for details). Three dogs were re-examined, but the owners declined further surgery (two had a good response and one had a moderate response), and three did not return for postoperative reexamination.
Twenty-four dogs (72·7%) still had some blood flow through the CPSS on portovenography but were able to tolerate complete attenuation; two dogs (6·1%) still had observable blood flow through the CPSS but only tolerated further partial attenuation (one due to extensive adhesions preventing further dissection and one due to portal hypertension); three dogs (9·1%) had progressed to full attenuation with no blood flow through the CPSS on portovenography ; and four dogs (12·1%) had developed multiple acquired shunts. The CPSS had been ligated with polypropylene alone in the three dogs that progressed to full attenuation. Overall, 27 dogs (81·8%) of 33 achieved full attenuation of their CPSS in two surgeries. This is summarised in Fig 1 . Twenty-three dogs (69·7%) had another surgical procedure performed at the time of the second CPSS surgery: 15 ovariohysterectomy (OVH), six castration, one ovariectomy and one entropion correction. Neutering was performed in all three of the dogs that had progressed to full attenuation spontaneously and two of the dogs that had developed multiple acquired shunts.
There was one intraoperative complication (3·0%) where it was not possible to achieve full attenuation due to the presence of marked adhesions following the previous surgery, although further attenuation was possible. Seven dogs (21·2%) suffered a postoperative complication (Table 6 ). No dogs died or were euthanased in the immediate postoperative period, with all 33 dogs discharged from the hospital. The median duration of hospitalisation was 4 days (range 1 to 7). One dog that had developed multiple acquired shunts and could not tolerate further attenuation started showing neurological signs 5 days after the surgery following discharge from the hospital. The dog was euthanased later that day by the referring veterinary surgeon. The overall postoperative mortality rate was one of 33 (3·0%).
Short-term postoperative re-examination
Eight out of 10 dogs (80%) that were treated with complete attenuation were re-examined in the short term after surgery (two by the referring vet) (see Table 7 for details). One dog with a good outcome had multiple acquired shunts identified on follow-up portovenography. Fourteen out of 32 dogs (43·8%) initially treated with partial attenuation, and surviving their second shunt surgery, were re-examined in the short term (three by the referring vet) (see Table 8 for details). Two dogs had further attenuation of their shunt at a third surgery as follows. One dog with a moderate response to surgery had persistent shunting on portovenography, and further partial attenuation was performed. Complete attenuation was subsequently achieved at an additional surgery. Another dog with a good outcome had a very minimal amount of shunting on portovenography, performed at the same time as OVH, and this was treated with complete attenuation. In addition, one dog with a complete attenuation at their second surgery and a good response had multiple acquired shunts documented on a follow-up ultrasound scan.
Long-term follow-up
Of the 48 dogs that survived surgery, 13 dogs (27·1%) were lost to long-term follow-up. Of these 35 dogs, 25 (52·1%) were alive at a median follow-up of 33·5 months (range 7·4 to 103·1).
For three of these dogs, follow-up was limited to the fact that the dog was alive with a presumed good quality of life. Detailed information was available to grade outcomes in 22 of these dogs (see Table 9 ). One dog with an excellent outcome had mild visual impairment following postoperative blindness. One dog with a poor outcome was reported to drink a lot and tire easily. One dog with a poor outcome had experienced an episode of pyrexia of unknown origin and a separate episode of chronic diarrhoea. The dog was also considered to have some behavioural abnormalities. Neither dog with a poor outcome was on any medical management. The owners of all 22 dogs felt that their dogs had a good quality of life. Two of these dogs were documented to have died or been euthanased within 2 months of their follow-up, one due to gastric dilation and volvulus (GDV) and one due to suspected pulmonary neoplasia.
Ten dogs (20·8%) were confirmed to have died or been euthanased prior to follow-up. Three dogs died because of non-CPSSrelated causes, including one haemoabdomen, one liver mass resection and one dog fight. Four dogs were euthanased for CPSS or suspected CPSS-related causes: two dogs due to ongoing clinical signs, one dog due to aggression (presumed related to hepatic encephalopathy) and one dog due to liver disease. The cause of death was unknown in three dogs. The time from surgery to death was available for four dogs with a median of 68·7 months (range 7·8 to 105·5).
DISCUSSION
We have described the short-and long-term outcome for 55 dogs with IHCPSS treated with suture ligation in one or two surgeries. IHCPSS are technically more challenging than EHCPSS due to the location of the CPSS within the liver parenchyma. Therefore, intraoperative complications are a major concern, with haemorrhage reported in 6·7% to 33·1% of dogs in other studies (Komtebedde et al . 1991 , Hunt et al . 1996 , White et al . 1998 ). In the study reported here, four dogs (7·3%) suffered haemorrhage during IHCPSS dissection at first surgery, none of which resulted in intraoperative mortality or ultimately precluded shunt attenuation. The overall rate of intraoperative complications at first surgery was 14·5%, which is similar to that reported for endovascular treatment, with major intraoperative complications in 3% and minor complications in 12% of dogs (Weisse et al . 2014 ). However, the differences in the procedures, and therefore the type of complications seen, make direct comparison difficult.
Outcomes for intrahepatic portosystemic shunts
Previous studies have reported postoperative complication rates of 11·8% to 77% for suture ligation, 9·1% to 22·2% for ameroid constrictor placement and 54·5% for cellophane banding (Komtebedde et al . 1991 , Hunt et al . 1996 , Papazoglou et al . 2002 , Hunt et al . 2004 , Bright et al . 2006 , Mehl et al . 2007 ). We found a postoperative complication rate at first surgery of 43·6%. Complications vary widely in type and severity, and it is challenging to make direct comparisons between studies. The most common type of postoperative complication was categorised as portal hypertension/gastrointestinal, seen in 25·5% of dogs. These complications were grouped together as the underlying cause was not always clear. Four dogs (7·3%) suffered mild to moderate, self-limiting postoperative ascites. This finding is an expected sequel of acute CPSS attenuation and could therefore be considered a routine occurrence rather than a complication (Berent & Tobias 2012 ) . However, it was included for completeness.
The current study had a postoperative mortality rate at first surgery of 10·9%. This is comparable with previously reported rates of 5·9% to 22·6% for suture ligation, 0% to 9·1% for ameroid constrictor placement, 27·3% for cellophane bands and 0% for hydraulic occluder placement, particularly as many of these are relatively small studies (Komtebedde et al . 1991 , Hunt et al . 1996 , White et al . 1998 , Papazoglou et al . 2002 , Hunt et al . 2004 , Adin et al . 2006 , Bright et al . 2006 , Mehl et al . 2007 ). However, these results are not as good as those reported for endovascular treatment of IHCPSS with a postoperative complication rate of 14% and a postoperative mortality rate of 5·3% (Weisse et al . 2014 ). Nevertheless, we should be cautious in making direct comparisons between studies due to wide variation in study design and clinical variables. Of the six dogs that died at first surgery, two had gastroduodenal ulceration confirmed at post mortem examination, two had severe gastrointestinal haemorrhage suggestive of ulceration, and two had suspected portal hypertension (one possibly related to a portal thrombus). Dogs with IHCPSS appear to be predisposed to gastrointestinal ulceration (Weisse et al . 2014 ) . It is unclear whether the fatal postoperative complications seen in the current study relate to pre-existing gastrointestinal ulceration, postoperative portal hypertension, the use of perioperative NSAIDs earlier on in the cohort or a combination of these factors.
Several studies have suggested that dogs with IHCPSS and EHCPSS treated with partial attenuation could benefit from repeat surgery to achieve complete attenuation (Hottinger et al . 1995 , White et al . 1998 , Burton & White 2001 , Lee et al . 2006 . In one study, the outcome was improved for a proportion of IHCPSS dogs following an additional procedure (White et al . 1998 ) . The current study is the first to report a large cohort of IHCPSS dogs treated routinely in this manner. In common with previous reports, a minority of dogs (18·2%) could tolerate acute complete attenuation at first surgery. Repeat surgery was recommended in all dogs that survived a partial attenuation at first surgery, regardless of apparent response. Most of these dogs, 84·6%, had a second surgery, and this was associated with a reduced rate of complications (21·2%) compared with the first surgery and mortality in one dog with multiple acquired shunts (3·0%). When both first and second surgeries are taken together, this cohort of dogs had a mortality rate of seven of 55 dogs (12·7%). Of the dogs that could not tolerate a complete attenuation at first surgery, repeat surgery allowed complete attenuation in 81·8%, including three dogs that had progressed to complete attenuation spontaneously. Overall, 77·1% of surviving dogs had complete attenuation of their shunt in one or two surgeries. Despite this, two of these dogs were subsequently identified to have persistent shunting, and full attenuation was achieved at an additional surgery. In addition, two dogs were subsequently documented to have developed multiple acquired shunts on follow-up imaging. Overall, persistent shunting was demonstrated or suspected in 27·1% dogs (13/48). A limited number of dogs had followup imaging, and therefore, the exact rate of persistent shunting is unknown and may have been underestimated. However, this rate of persistent shunting compares well with a study of the use of ameroid constrictors in dogs with IHCPSS, which identified persistent shunting on scintigraphy in 43% of dogs (Mehl et al . 2007 ). The true significance of persistent shunting is unclear. In EHCPSS dogs treated with ameroid constrictors, those with a negative postoperative scintigraphy scans were greater than 10 times more likely to experience a successful outcome (Falls et al . 2013 ) . Intuitively, dogs that achieve a complete attenuation without persistent shunting should have a better outcome, although this is unproven. Our data support the concept that repeat surgery markedly increases the proportion of dogs that achieve complete attenuation and therefore reduces the proportion of dogs with persistent shunting compared with partial ligation alone and, potentially, the use of ameroid constrictors.
The current study focused on the short-term outcome of suture ligation of IHCPSS. However, long-term follow-up was available for some dogs with IHCPSS as part of another study validating a HRQOL questionnaire in a large group of dogs with EHCPSS and IHCPSS, and follow-up was also conducted for dogs that were not part of that study (unpublished data). Several studies have reported the long-term follow-up of dogs treated for IHCPSS, typically assessing outcomes through simple owner assessment, although the wide variations in the precise definition of a successful outcome, the data reported and the follow-up times makes direct comparison challenging. In a large study of endovascular occlusion, 19% of dogs had a poor outcome, with continued or worsening clinical signs despite medical management or surgical-related death at a median of 32 months after treatment (Weisse et al . 2014 ) . In two studies of ameroid constrictor placement, a poor outcome, with euthanasia due to persistence or recurrent clinical signs was reported in 12·5% to 30% of dogs at an average of 28·5 to 38·3 months postsurgery (Bright et al . 2006 , Mehl et al . 2007 . In three studies of suture ligation, 0% to 16·3% of dogs had a poor outcome, with recurrent or persistent signs and/or shunting at an average of 18 to 50 months postsurgery (White et al . 1998 , Mehl et al . 2007 ). We assessed the long-term outcome of 22 dogs alive at a median time of 29 months postoperatively. Of these 22 dogs, 20 (90·9%) had an excellent or fair outcome, with a poor outcome observed in two dogs (9·1%). Additionally, a further three dogs had an apparently good outcome but without sufficient detail to categorise this further. This overall outcome is very good and compares favourably with other techniques, although detailed follow-up was only available for 45·8% of the dogs in our study. Overall, 14 of 17 dogs (82·4%) that had complete attenuation of their shunt had an excellent outcome in comparison with one of five dogs (20%) that had documented or suspected persistent shunting. Although, the number of dogs with persistent shunting is small, these data do suggest that dogs with complete attenuation and no persistent shunting are more likely to have an excellent long-term outcome. This would support our recommendation for follow-up surgery in dogs with persistent shunting.
We explored the possible association between age, study period and use of NSAIDs with mortality following first surgery. Due to the small number of dogs and the retrospective nature of the study, it was not considered appropriate to statistically analyse the data. Future, prospective studies may want to explore these factors in more detail. Interestingly, dogs that died during the postoperative period were younger than those that survived. It is not clear why that may be the case. As most of the dogs died due to complications related to gastrointestinal bleeding or portal hypertension, it is not clear why this would be. It is possible that younger dogs are more at risk of gastrointestinal bleeding, but this remains unproven. The mortality rate was greater in the first part of the study period. This apparent improvement could have related to greater experience in determining the degree of attenuation and thus a reduced risk of portal hypertension. This could also have been associated with general improvements in the anaesthetic and postoperative management of these dogs over time, although the study did not look at these aspects specifically. Mortality at first surgery appeared to be associated with the use of NSAIDs. All four of the dogs that died because of confirmed or suspected gastroduodenal ulceration had received NSAIDs postoperatively. NSAIDs are a risk factor for gastrointestinal Journal of Small Animal Practice • Vol 59 • April 2018 • © 2017 British Small Animal Veterinary Association ulceration due to their effect on prostaglandin synthesis and gastric mucosal integrity (Stanton & Bright 1989 , Cariou et al . 2009b . As previously mentioned, dogs with IHCPSS appear to be predisposed to gastrointestinal ulceration (Weisse et al . 2014 ) . Therefore, the use of NSAIDs in these dogs may have contributed to these complications. There were no complications or mortality related to gastrointestinal haemorrhage at second surgery, despite the use of NSAIDs. We believe that this is because all dogs undergoing repeat surgery had previously had a partial shunt ligation, and therefore, their portal blood flow and, hence, liver function should have been improved. This presumably makes them less vulnerable to surgical complications, particularly those that could have been precipitated by NSAID use. The authors no longer use NSAIDs in dogs with IHCPSS or EHCPSS.
The current study has several limitations, primarily due to its retrospective nature. All dogs were operated on at a single centre and over a long period of time. Importantly, a proportion of dogs (27·1%) were lost to long-term follow-up. Determining the longterm outcome of dogs treated for IHCPSS is challenging, partly due to the lack of a 'gold-standard' assessment method. A more comprehensive follow-up, with owner assessment of quality of life, dynamic bile acids and imaging studies to detect persistent shunting, in all dogs would have strengthened the findings of our study. A prospective study looking at the long-term outcome of dogs surgically treated for IHCPSS would allow firmer conclusions to be drawn.
This study demonstrates that complete suture attenuation of IHCPSS in one or two surgeries is associated with a good longterm outcome. For dogs that could not tolerate complete ligation at first surgery, repeat surgery was associated with a lower rate of complications and a good rate of complete attenuation. The long-term outcome was excellent in a high proportion (82·4%) of dogs that had complete attenuation in one or two surgeries, compared with those with persistent shunting where a minority (20%) had an excellent outcome. Further work is needed to clarify the exact significance of persistent shunting on long-term outcome and quality of life.
